Loading company…
Vitalgen develops gene delivery, gene editing and gene therapy technologies.
Founded in 2020 and based in Shanghai, Vitalgen develops gene delivery and editing technologies, including ViVec® AAV vectors, ViLNP® lipid nanoparticles and ViCas® CRISPR. Its programs target genetic and neurodegenerative disorders, including AADC deficiency and amyotrophic lateral sclerosis (ALS). The company is advancing products into clinical research and works with biopharmaceutical companies. In September 2025, it closed venture funding from Cinda Capital, Maotian Capital and Shanghai Xuhui Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in